...
首页> 外文期刊>Clinical Laboratory Science: Journal of the American Society for Medical Technology >Venous Thrombosis with Both Heterozygous Factor V Leiden (R507Q) and Factor II (G20210A) Mutations
【24h】

Venous Thrombosis with Both Heterozygous Factor V Leiden (R507Q) and Factor II (G20210A) Mutations

机译:静脉血栓形成同时具有杂合因子V莱顿(R507Q)和因子II(G20210A)突变

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Both hereditary and acquired factors increase the risk of venous thromboembolism, thus the clinical management of affected patients involves evaluation of genetic factors that predispose to hypercoagulability. Factor V Leiden (R507Q) and factor II (prothrombin) mutation (G20210A) are the two most common inherited hypercoagulability disorders among populations of European origin. Both factor V Leiden and factor II mutation (G20210A) represent gain-of-function mutations: factor V Leiden causes resistance to activated protein C, and factor II mutation (G20210A) results in higher levels of plasma prothrombin. Herein, we present an uncommon case of combined factor V Leiden mutation (R507Q) and factor II mutation (G20210A), and discuss the prevalence and features of each entity, as well as their role in the clinical management of affected patients.
机译:遗传因素和后天因素都增加了静脉血栓栓塞的风险,因此,对患病患者的临床管理包括对易引起高凝性的遗传因素进行评估。因子V莱顿(R507Q)和因子II(凝血酶原)突变(G20210A)是欧洲血统人群中最常见的两种遗传性高凝性疾病。因子V莱顿和因子II突变(G20210A)均代表功能获得性突变:因子V莱顿引起对活化蛋白C的抗性,因子II突变(G20210A)导致血浆凝血酶原水平更高。在本文中,我们介绍了一个罕见的V型莱顿因子突变(R507Q)和II型因子突变(G20210A)合并病例,并讨论了每个实体的患病率和特征以及它们在受影响患者的临床管理中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号